Kos Announces Annual Shareholders Meeting April 27, 2006
19 April 2006 - 4:25PM
Business Wire
Kos Pharmaceuticals, Inc. (Nasdaq:KOSP) today announced that the
2006 Annual Shareholders Meeting will be held on April 27, 2006 at
the W Hotel New York, 541 Lexington Avenue, New York, NY 10022. The
meeting will take place at 10:00 am ET. Interested parties can
access the webcast information by going to the Investor Relations
section of Kos' website at www.kospharm.com, and referencing
upcoming events. About Kos Kos Pharmaceuticals, Inc. is a fully
integrated specialty pharmaceutical company engaged in developing,
commercializing, manufacturing and marketing proprietary
prescription products for the treatment of chronic diseases with a
particular focus on the cardiovascular, metabolic and respiratory
disease areas. The Company's principal product development strategy
is to reformulate existing pharmaceutical products with large
market potential to improve safety, efficacy, and patient
compliance. Kos' strategy also includes making measured investments
in new chemical entity research through in-house and sponsored
research, scientific in-licensing and general corporate development
activities. The Company currently markets Niaspan(R) and Advicor(R)
for the treatment of cholesterol disorders, Azmacort(R) for the
treatment of asthma, Cardizem(R)LA for the treatment of
hypertension and angina, and Teveten(R) and Teveten(R)HCT for the
treatment of hypertension. Kos has a strong and growing research
and development pipeline including proprietary drug delivery
technologies in solid-dose, inhalation and aerosol metered-dose
device administration to help fuel sustained, organic sales growth
into the future. Certain statements in this press release,
including statements relating to the Company's strong and growing
research and development pipeline and future sales growth are
forward-looking and are subject to risks and uncertainties which
may cause actual results to differ materially from those projected
in a forward-looking statement. These risks and uncertainties
include, the Company's ability to attract and retain sales
professionals and increase the size of its sales force, the
Company's ability to successfully develop (both internally and
through sponsored research arrangements with third parties) and
commercialize new products under development and within expected
timeframes, the Company's ability to successfully negotiate
additional important strategic business development and corporate
opportunities, the progress of the Company's research and
development pipeline, the protection afforded by the Company's
patents and those related to the acquired and licensed products,
the effect of conditions in the pharmaceutical industry and the
economy in general, the Company's ability to maintain compliance
with FDA standards without adversely affecting its manufacturing
capability or ability to meet its production requirements, the
Company's ability to ensure compliance with prescription drug sales
and marketing laws and regulations, changes in the regulatory
environment governing the Company's compliance with FDA. A more
detailed discussion of risks attendant to the forward-looking
statements included in this press release are set forth in the
"Forward-Looking Information: Certain Cautionary Statements"
section of the Company's Annual Report on Form 10-K for the year
ended December 31, 2005, filed with the Securities and Exchange
Commission, and in other reports filed with the SEC.
Kos (NASDAQ:KOSP)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Kos (NASDAQ:KOSP)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Kos Pharmaceuticals (NASDAQ): 0 Nachrichtenartikel
Weitere Kos Pharmaceuticals, Inc. News-Artikel